Chris - all good points
MANF ophthalmology program is focused on RP
MANF & CDNF are being combined to treat Antibiotic-Induced Ototoxicity (ear) and is also considered to be an orphan indication
Need more drill down on updates for LymPro TBI/CE and MANF "buisness development" reminder from GC
from latest 08/10/14 Blog:
http://www.thechairmansblog.com/amarantus-bio...iuwyO.dpuf
1.) The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter; (Sept.)
2.) We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward. (done - ICON Labs)
3.) We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro). (LP-002 Studies to be completed 4Q14)
4.) We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID) (expected 4Q14)
We have significant announcements forthcoming in the weeks and months ahead for MANF including the complete data sets regarding ophthalmological toxicology studies, Retinitis Pigmentosa functional data assessments and additional efficacy data sets, initial data from our research collaboration with the University of Washington on Wolfram’s Syndrome retinal degeneration, intracranial delivery data for our Parkinson’s program collaboration with Renishaw, additional data from undisclosed activities for MANF, the initiation of GMP manufacturing in preparation for first-in-man studies, the filing of Orphan Drug Designation for MANF in Retinitis Pigmentosa, and potential business development activity around the MANF Program.
MANF ophthalmology program is focused on RP
MANF & CDNF are being combined to treat Antibiotic-Induced Ototoxicity (ear) and is also considered to be an orphan indication
Need more drill down on updates for LymPro TBI/CE and MANF "buisness development" reminder from GC
from latest 08/10/14 Blog:
http://www.thechairmansblog.com/amarantus-bio...iuwyO.dpuf
1.) The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter; (Sept.)
2.) We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward. (done - ICON Labs)
3.) We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro). (LP-002 Studies to be completed 4Q14)
4.) We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID) (expected 4Q14)
We have significant announcements forthcoming in the weeks and months ahead for MANF including the complete data sets regarding ophthalmological toxicology studies, Retinitis Pigmentosa functional data assessments and additional efficacy data sets, initial data from our research collaboration with the University of Washington on Wolfram’s Syndrome retinal degeneration, intracranial delivery data for our Parkinson’s program collaboration with Renishaw, additional data from undisclosed activities for MANF, the initiation of GMP manufacturing in preparation for first-in-man studies, the filing of Orphan Drug Designation for MANF in Retinitis Pigmentosa, and potential business development activity around the MANF Program.
